ArticleFrontiers in nutrition2025
Increase in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut hormones in POTS and their relation to hemodynamic parameters and gastrointestinal symptoms.Scientific reports · 2026Article
- G Protein-Coupled Receptors in Irritable Bowel Syndrome: Mechanisms and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) as well as glucagon-like peptide-1 (GLP-1) have independently been implicated in irritable bowel syndrome (IBS) pathophysiology. However, there is a lack of studies that assess how low FODMAP diet affects circulating GLP-1 levels in IBS patients. Methods: Thirty patients with either diarrhea or mixed type IBS were recruited and undertook low FODMAP diet for 12 weeks. Plasma GLP-1 levels, IBS Severity Scoring System (IBS-SSS), body weight and FODMAP intake were assessed before and after the 12-week dietary intervention. Key results: Following a low FODMAP diet, average IBS-SSS and body weight were reduced ( Conclusion: Our study indicates that a 12-week low FODMAP diet may increase plasma glucagon-like peptide-1 levels in IBS patients. The underlying mechanism for this increase remains to be understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.